SPECIAL REPORT
Pregnancy and MS
Effect of treatment on postpartum relapses
Pregnancy outcomes in treated patients
Fetal and neonate drug exposure with ocrelizumab
Quick poll on pregnancy and MS
Submit your answers to reveal how your colleagues voted (respondents remain anonymous)
SPECIAL REPORT
While there is a growing consensus on the benefits of initiating treatment with a higher-efficacy (HE) disease-modifying therapy (DMT) in MS, there are a few considerations in clinical practice that need to be addressed. The key issues include the efficacy of HE DMTs relative to lower-efficacy therapies in slowing disability worsening; whether anti-CD20 monoclonal antibody agents (e.g. ofatumumab, ocrelizumab), which primarily target inflammatory disease activity, have an impact on progression independent of relapse activity (PIRA); how switching therapies may optimize outcomes; and whether long-term drug exposure is safe. Read More
The 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – 18-20 September 2024
The following summarizes some of the highlights from Day 3 of ECTRIMS 2024.
The 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – 18-20 September 2024
The following summarizes some of the highlights from Day 2 of ECTRIMS 2024.
The 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – 18-20 September 2024
Please note that the NeuroSens ECTRIMS 2024 Highlights slide resource, developed in collaboration with Dr. Daniel Selchen, BARLO MS Centre, Toronto, will be available as of October 10th, on request only. Make your request now by completing the online form. Industry members can also use this form to request to sponsor a NeuroSens post-ECTRIMS event (in-person or virtual). For more information, contact us at info@neuro-sens.com. Read More